Patient Longevity Outcomes of Conservative Strategies Versus Radical Prostatectomy for Localized Prostate Cancer: A Meta-analysis With Trial Sequential Analysis
In brief
Watchful waiting linked to roughly twice the mortality of prostate surgery
Across 12 studies of 36,993 patients, watchful waiting was associated with about twice the cancer-specific and overall mortality seen after prostate surgery. Active surveillance showed no statistically significant mortality difference from surgery, but the evidence was too limited to rule one out. These comparisons do not establish cause, so patient selection and life expectancy remain central to treatment decisions.
- Journal
- Clinical genitourinary cancer (Q1)
- Published
- 12 October 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Adel Jorge El Rassi, Carlos A Garcia-Becerra, Davi Alves Silva, Beatriz Rizzo Parreira, Alex Resende Allig, Felipe Araujo Gouhie, et al.
- PMID
- 43020765
- DOI
- 10.1016/j.clgc.2026.102689
Why clinicians should know about it
- Picked for Urology (paper of the day, 14 November 2026): Localized prostate cancer surveillance versus surgery outcomes
Abstract
Management of localized low-intermediate risk prostate cancer remains controversial. Radical prostatectomy (RP) is a curative option but is associated with treatment-related morbidity, while conservative strategies such as active surveillance (AS) and watchful waiting (WW) aim to avoid overtreatment. This systematic review and meta-analysis evaluated the impact of AS and WW compared with RP on cancer-specific and all-cause mortality. A systematic review was conducted according to the PRISMA Statement and registered protocol (CRD420251032309). PubMed, Embase, and Cochrane databases were searched for studies comparing AS or WW with RP in localized prostate cancer. Random-effects meta-analyses using risk ratios (RRs) were performed for cancer-specific and all-cause mortality. A sensitivity analyses used leave-one-out methods. Trial Sequential Analysis evaluated the robustness and statistical power of the evidence. Twelve studies involving 36,993 patients were included. Comparisons between AS and RP showed no statistically significant differences in cancer-specific mortality (risk ratios [RR] 1.44; 95% confidence interval [CI] 0.43-4.79) or all-cause mortality (RR 1.77; 95% CI 0.98-3.20). Trial sequential analysis indicated insufficient information size, suggesting the evidence remains underpowered. In contrast, WW was associated with significantly higher cancer-specific mortality (RR 2.23; 95% CI 1.19-4.19) and all-cause mortality (RR 2.20; 95% CI 1.59-3.05) compared with RP, with sequential analysis supporting these findings. AS demonstrates comparable mortality outcomes to RP in appropriately selected patients with localized prostate cancer, although current evidence remains statistically underpowered. Conversely, WW is associated with worse survival outcomes than RP. Treatment decisions should incorporate patient characteristics, life expectancy, and shared decision-making.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.